COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME

摘要

A combination preparation comprising an inhibitor of HMG-CoA(3-hydroxy-3-methylglutaryl-coenzyme A) reductase and aspirin is provided to remove the side effects due to different medical effects, and reduce the pathogenic risk factor of the cardiovascular disease, thereby reducing the long-term prevention expense. The combination preparation for preventing and treating cardiovascular disease comprises (i) 0.5-80.0 mg of the inhibitor of HMG-CoA reductase which is firstly released from the human body and (ii) 20.0-700.0 mg of aspirin which is secondly released from the human body after 15 minutes to 4 hours after release of the inhibitor of HMG-CoA reductase, wherein the combination preparation is released from the different absorption sites of human body or sequentially released from the same absorption site.